As the next generation of immune-modulating therapies grows more complex, so does the challenge of accurately assessing their safety profiles.
Although the fundamental principles of immunotoxicology remain constant, the tools, context and collaborative approaches required to evaluate risk are shifting.
Drug developers are increasingly required to anticipate unpredictable immune responses using a more integrated and biomarker-informed approach.
The primary goal of such a strategy is to bridge the gap between preclinical and clinical data more precisely.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.